Showing 1 - 10 of 11 Hematologic Cancers

Status: Open Not Enrolling

Investigator: Shilpan Shah

Study Coordinator:

Phone:

The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with CLL/SLL who have been previously treated with at least one prior line of th ... Read more >

Status: Enrolling

Investigator: Siddhartha Ganguly

Study Coordinator: Danielle Sewall

Phone: 346.238.2674

The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab i ... Read more >

Status: Enrolling

Investigator: Siddhartha Ganguly

Study Coordinator: Britney Nguyen

Phone: 713.441.0685

The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dexametha ... Read more >

Status: Open Not Enrolling

Investigator: Shilpan Shah

Study Coordinator:

Phone:

The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL. Participants may or may not have already had treatment for their cancer. Participation could last up to six y ... Read more >

Status: Open Not Enrolling

Investigator: Shilpan Shah

Study Coordinator: Danielle Sewall

Phone: 346.238.2674

This will be a multicenter Phase II open-label study of asciminib in CML-CP patients who have been previously treated with one prior ATP- binding site TKI with discontinuation due to treatment failure, warning or intolerance. (2L patient cohort) ... Read more >

Status: Enrolling

Investigator: Siddhartha Ganguly

Study Coordinator: Britney Nguyen

Phone: 713.441.0685

This phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell [CAR-T] therapy) for multiple myeloma. The ... Read more >

Status: Enrolling

Investigator: Siddhartha Ganguly

Study Coordinator: Danielle Sewall

Phone: 346.238.2674

The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). ... Read more >

Status: Open Not Enrolling

Investigator: Siddhartha Ganguly

Study Coordinator: Danielle Grbavac

Phone: 346.238.4456

A phase 1b/2, open label, multi-center, Clinical Study of Chimeric Antigen Receptor T Cells targeting BCMA in patients with relapsed and or refractory multiple myeloma. ... Read more >

Status: Enrolling

Investigator: Sai ravi kiran Pingali

Study Coordinator: Danielle Grbavac

Phone: 346.238.4456

This is a Phase IB/II trial that will investigate the safety, tolerability and efficacy of combination therapy using All-Trans Retinoic Acid (ATRA) with Carfilzomib based therapies in plasma cell myeloma also commonly referred as Multiple Myelom ... Read more >

Status: Open Not Enrolling

Investigator: Sai ravi kiran Pingali

Study Coordinator: Natolie Hamilton

Phone: 469.267.9275

This is a laboratory-based study supported by NIH funding. It is aimed to explore the therapeutic effects of novel molecules or antigens to treat hematologic diseases. In order to complete these studies, samples including peripheral blood, bone ... Read more >

Status: Enrolling

Investigator: Shilpan Shah

Study Coordinator: Danielle Grbavac

Phone: 346.238.4456

This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with ... Read more >